-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 29, 2021/PRNewswire/ - Everest Medicines (HKEX 1952.
Zhu Xu, Chief Medical Officer of Genting Sunshine Infections, said: “Complicated intra-abdominal infections are still the main clinical bacterial infectious disease
XeravaTM is currently approved for the treatment of complex intra-abdominal infections in adults in the United States, the European Union, the United Kingdom and Singapore, and the drug marketing authorization application in Mainland China is under review
In September 2020, XeravaTM was included in the latest clinical guidelines issued by the Infectious Diseases Society of America (IDSA) for the treatment of Gram-negative bacterial infections
About complicated intra-abdominal infections
Complex intra-abdominal infection (cIAI) is a nosocomial or community-acquired infection that involves peritonitis or abscesses formed from hollow organs to the peritoneal cavity
About XeravaTM (Elacycline)
XeravaTM (Elacycline) is a new, fully synthetic, broad-spectrum, fluorotetracycline-containing intravenous antibacterial drug, used to treat multiple infections including Gram-negative bacteria and Gram-positive bacteria that are common in China.
About Genting Shinyao
Genting Xinyao is a biopharmaceutical company focusing on the development and commercialization of innovative drugs, dedicated to meeting the unmet medical needs of the Asian market
Source: Genting Shinyao